ReviewPharmaceuticals (Basel, Switzerland)2020
Bullous Central Serous Chorioretinopathy: A Rare and Atypical Form of Central Serous Chorioretinopathy. A Systematic Review.
Review in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Half-Dose Photodynamic Therapy for Bullous Variant Central Serous Chorioretinopathy: A Long-Term Follow-Up.Ophthalmology and therapy · 2026Article
- Pachychoroid diseases of the macula: an update.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
- Oral Eplerenone for Exudative Retinal Detachment Secondary to Central Serous Chorioretinopathy: A Case Report.Cureus · 2025Article
- Article
- Bullous central serous chorioretinopathy with retinal pigment epithelial macro rip treated with eplerenone monotherapy.BMJ case reports · 2024Article
- External Subretinal Fluid Drainage and Vitrectomy in Exudative Retinal Detachment Secondary to Central Serous Chorioretinopathy: A Case Report.Korean journal of ophthalmology : KJO · 2022Article
- Bilateral bullous central serous chorioretinopathy treated with PDT and eplerenone.American journal of ophthalmology case reports · 2022Article
- Intravitreous injection of conbercept for bullous retinal detachment: A case report.World journal of clinical cases · 2022Article
- Extreme Interocular Asymmetry in an Atypical Case of a Hydroxychloroquine-Related Retinopathy.Medicina (Kaunas, Lithuania) · 2022Article
- Atypical Chronic Central Serous Chorioretinopathy Mimicking Vogt-Koyanagi-Harada Disease: Full Therapeutic Response to Half-Fluence Photodynamic TherapyTurkish journal of ophthalmology · 2022Article
- Imbalance in the Levels of Angiogenic Factors in Patients with Acute and Chronic Central Serous Chorioretinopathy.Journal of clinical medicine · 2021Article
- Morphological Changes and Prognostic Factors before and after Photodynamic Therapy for Central Serous Chorioretinopathy.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Central Serous Chorioretinopathy Classification.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Rate of misdiagnosis and clinical usefulness of the correct diagnosis in exudative neovascular maculopathy secondary to AMD versus pachychoroid disease.Scientific reports · 2020Observational
- Current Choroidal Imaging Findings in Central Serous Chorioretinopathy.Vision (Basel, Switzerland) · 2020Review
- Surgical Approaches to Serous Retinal Detachment With Retina-Lens Touch in Eyes With Nanophthalmos.Journal of vitreoretinal diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous central serous chorioretinopathy (bCSCR) is a rare variant of the central serous chorioretinopathy, complicated by an exudative retinal detachment with shifting fluid. This systematic review aims to present the epidemiology, the pathogenesis, the clinical presentation, the imaging, the differential diagnosis, and the latest treatments of this disease. A total of 60 studies were identified following a literature search adhering to PRISMA guidelines. After full-text evaluation, 34 studies about bCSCR were included. bCSCR usually affects middle-aged men, and the principal risk factor is corticosteroid medications. Pathogenesis is related to an increased choroidal vessel and choriocapillaris permeability, with subsequent subretinal fluid accumulation, rich in fibrin, which may provoke the exudative retinal detachment. Clinical presentation and imaging are fundamental to distinguish bCSCR from other pathologies, avoiding unappropriated treatment. Corticosteroid withdraws (if assumed) and laser photocoagulation of leakage sites seen at angiography may speed up retinal reattachment. Verteporfin photodynamic therapy, transpupillary thermal therapy, oral eplerenone and scleral thinning surgery are other therapeutic options. An early diagnosis might prevent disease progression due to harmful medications as well as unnecessary surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.